Curis Lifesciences Q3 FY26 Share Price & Earnings Call Analysis
- Market cap
- ₹146 Cr
- P/E
- 21.10
- ROE
- 21.70%
- PEG
- 0.28
- Price to sales
- 2.41
- Debt to equity
- 0.46
- 52W high / low
- ₹230 / ₹88.8
- EBITDA margin
- 18.36%
- Net profit margin
- 11.43%
- Promoter holding
- 68.03%
- Sales (last year)
- ₹61 Cr
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.[1]
Guidance scorecard · Q3 FY26 call
What Curis Lifesciences Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
RevenueQ3 FY26 call
10–20%- Curis Lifesciences plans to focus on own brand marketing, especially in Nigeria, Kenya, and Ghana, aiming to increase revenue from this segment from about 1% currently to 5-7% by FY27 and beyond.
- The company expects registration of 10 products in Nigeria by FY27, and expanded own brand marketing to contribute significantly to growth post-registration, likely by FY28.
- Merchant export and contract manufacturing revenues will progressively be replaced by higher-margin own brand products over 3-5 years, targeting 80% capacity utilization with 80% revenue from own brand marketing.
- Expansion will be supported by strategic partnerships, such as with Eurosun Pharmaceuticals in Nigeria, leveraging their local market knowledge.
2 more points from Curis Lifesciences Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ3 FY26 call
Up 2%+See what Curis Lifesciences Ltd said on margins — free account, 30 seconds.
CapexQ3 FY26 call
None planned- No major capex is planned currently; the company already has all required manufacturing machines.
- Focus is on utilizing existing capacity with improved working capital from the IPO for scaling operations.
- Capacity utilization target: 80%+ over the next 2-3 years without significant new capex.
- The company is shifting from low-margin job work towards higher-margin own-brand exports, which requires regulatory registrations and market development rather than heavy capital investments.
- Strategic investments involve product registrations and expanding market presence, especially in African markets like Nigeria and Kenya, through partnerships rather than large capital outlays.
2 more points from Curis Lifesciences Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ3 FY26 call
See what Curis Lifesciences Ltd said on fundraising — free account, 30 seconds.
Order bookQ3 FY26 call
- Currently, orders from 3 products in Kenya and 9 products from Yemen are active, but expected revenue from these is not significant in the next financial year.
- Nigeria is identified as a very good market with high potential, but financial constraints delayed product registration and entry; Nigeria is now prioritized for registration and marketing.
- Expansion plans include entering own-brand marketing with registration in Nigeria followed by scaling up products in Kenya for increased revenue.
- New product registrations are ongoing with registration timelines staggered; some products registered by FY23 end but commercial scale-up and revenue gains will take 1-2 years.
- Merchant exporter-driven contract manufacturing continues with stable existing orders replacing low-margin jobs.
2 more points from Curis Lifesciences Ltd's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Curis Lifesciences Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Curis Lifesciences Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Curis Lifesciences Ltd
Quarterly Results
Quarter-by-quarter operating performance
Financials of Curis Lifesciences Ltd
Profit & Loss
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| Sales + | 23.70 | 35.21 | 35.13 | 49.13 | 62.27 |
| Expenses + | 20.12 | 31.95 | 26.74 | 39.59 | 49.35 |
| Operating Profit | 3.58 | 3.26 | 8.39 | 9.54 | 12.92 |
| OPM % | 15.11% | 9.26% | 23.88% | 19.42% | 20.75% |
| Other Income + | 0.02 | 0.34 | 0.31 | 0.51 | 0.05 |
| Interest | 1.62 | 1.33 | 0.85 | 1.11 | 1.04 |
| Depreciation | 0.75 | 0.73 | 0.68 | 0.67 | 0.68 |
| Profit before tax | 1.23 | 1.54 | 7.17 | 8.27 | 11.25 |
| Tax % | 59.35% | 20.13% | 32.22% | 26.24% | |
| Net Profit + | 0.49 | 1.23 | 4.87 | 6.11 | 8.21 |
| EPS in Rs | 9.80 | 24.60 | 97.40 | 10.30 | 13.83 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of Curis Lifesciences Ltd
Balance Sheet
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 0.50 | 0.50 | 0.50 | 5.93 | 5.93 |
| Reserves | -1.40 | -0.18 | 5.37 | 10.29 | 14.49 |
| Borrowings + | 17.62 | 16.19 | 17.09 | 15.61 | 14.81 |
| Other Liabilities + | 10.68 | 13.16 | 10.91 | 10.70 | 14.16 |
| Total Liabilities | 27.40 | 29.67 | 33.87 | 42.53 | 49.39 |
| Fixed Assets + | 12.33 | 12.20 | 11.59 | 10.99 | 10.78 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other Assets + | 15.06 | 17.46 | 22.27 | 31.51 | 38.58 |
| Total Assets | 27.40 | 29.67 | 33.87 | 42.53 | 49.39 |
Financials of Curis Lifesciences Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Cash from Operating Activity + | 4.95 | 3.35 | 0.28 | -1.76 |
| Cash from Investing Activity + | -0.37 | -0.55 | -0.06 | -0.02 |
| Cash from Financing Activity + | -4.58 | -2.76 | 0.05 | 1.67 |
| Net Cash Flow | -0.01 | 0.04 | 0.27 | -0.11 |
| Free Cash Flow | 4.56 | 2.77 | 0.21 | -1.85 |
| CFO/OP | 138% | 103% | 3% | -2% |
Financials of Curis Lifesciences Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 96.10 | 98.17 | 104.94 | 55.87 |
| Inventory Days | 208.46 | 114.92 | 273.22 | 347.26 |
| Days Payable | 359.58 | 262.67 | 210.40 | 112.29 |
| Cash Conversion Cycle | -55.01 | -49.58 | 167.75 | 290.83 |
| Working Capital Days | -16.02 | -20.84 | 36.26 | 99.63 |
| ROCE % | 17.21% | 40.64% | 34.24% |
Continue your research
What Curis Lifesciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY